MORRISTOWN MEDICAL CENTER

Type: Teaching hospital
Where: MORRISTOWN, NJ
Medicare CCN: 310015
Received: $5,021,426 in 688 records, 2019 ($312,964 general, $4,708,462 research)
Source: CMS Open Payments search ↗

By year

Program year	Kind	Records	Amount
2019	General payment	141	$312,964
2019	Research payment	547	$4,708,462

By company

Company	Records	Amount	Years
Edwards Lifesciences Corporation	139	$3,079,029	2019
Medtronic Vascular, Inc.	70	$304,386	2019
TESARO, Inc.	18	$230,442	2019
Amgen Inc.	14	$224,052	2019
ImClone Systems, LLC	10	$172,359	2019
SANOFI PASTEUR INC.	2	$121,785	2019
Merck Sharp & Dohme LLC	107	$112,455	2019
VERTEX PHARMACEUTICALS INCORPORATED	3	$69,682	2019
Abbott Laboratories	46	$64,323	2019
BioMarin Pharmaceutical Inc.	21	$51,660	2019
AstraZeneca Pharmaceuticals LP	10	$50,122	2019
ABBVIE INC.	29	$46,442	2019
PFIZER INC.	11	$46,088	2019
E.R. Squibb & Sons, L.L.C.	5	$45,838	2019
SANOFI US SERVICES INC.	3	$44,283	2019
Eli Lilly and Company	3	$34,158	2019
AstraZeneca UK Limited	2	$28,057	2019
Medtronic, Inc.	7	$21,379	2019
GENZYME CORPORATION	13	$21,090	2019
ARRAY BIOPHARMA INC	8	$20,150	2019
Novartis Pharmaceuticals Corporation	7	$16,866	2019
Ipsen Innovation	5	$15,950	2019
Takeda Pharmaceuticals U.S.A., Inc.	1	$15,455	2019
Dynavax Technologies Corporation	5	$12,637	2019
Medical Device Business Services, Inc.	5	$12,450	2019
Sterilmed, Inc.	11	$12,364	2019
GE HEALTHCARE	2	$10,500	2019
Allergan, Inc.	8	$10,017	2019
BioFire Diagnostics, LLC	1	$9,300	2019
Janssen Research & Development, LLC	10	$8,619	2019
Insmed, Inc.	5	$8,200	2019
Stryker Corporation	4	$7,548	2019
Regeneron Pharmaceuticals, Inc.	6	$6,750	2019
Astellas Pharma Global Development	3	$6,013	2019
Bayer Healthcare Pharmaceuticals Inc.	3	$5,750	2019
Medline Industries LP	5	$5,650	2019
KARL STORZ Endoscopy-America	39	$5,420	2019
Boston Scientific Corporation	3	$5,000	2019
Janssen Biotech, Inc.	3	$4,750	2019
Siemens Medical Solutions USA, Inc.	1	$4,308	2019
ZOLL Circulation Inc	1	$4,010	2019
Mallinckrodt Enterprises LLC	4	$4,000	2019
Lilly USA, LLC	3	$3,850	2019
Cardiovascular Systems Inc.	3	$3,454	2019
MicroVention, Inc.	2	$3,350	2019
Incyte Corporation	3	$2,737	2019
PORTOLA PHARMACEUTICALS, LLC	2	$2,550	2019
Amarin Pharma, Inc.	1	$2,500	2019
LANTHEUS MEDICAL IMAGING, INC.	1	$2,500	2019
Smith+Nephew, Inc.	1	$2,424	2019

By nature of payment

Nature	Records	Amount
Research payment	547	$4,708,462
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	43	$199,871
Space rental or facility fees (teaching hospital only)	41	$65,350
Gift	37	$21,958
Charitable Contribution	3	$9,508
Education	11	$9,186
Grant	4	$7,000
Food and Beverage	2	$89

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2019-12-31	Stryker Corporation	$4,651	Gift	In-kind items and services	NSE - HIGH SPEED DRILLS Device, NEURO SPINE ENT		2019
2019-12-31	Siemens Medical Solutions USA, Inc.	$4,308	Charitable Contribution	In-kind items and services			2019
2019-12-31	Stryker Corporation	$2,491	Gift	In-kind items and services	SURG - REMB Device, SURGICAL		2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$751	Research payment	In-kind items and services	IMFINZI Drug, Oncology	A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$269	Research payment	In-kind items and services	IMFINZI Drug, Oncology	Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic	2019
2019-12-31	Stryker Corporation	$5	Gift	Cash or cash equivalent	NONE Device, NONE		2019
2019-12-29	AstraZeneca Pharmaceuticals LP	$2,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	LYNPARZA Drug, Oncology		2019
2019-12-26	Janssen Research & Development, LLC	$996	Research payment	Cash or cash equivalent		A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo	2019
2019-12-23	Edwards Lifesciences Corporation	$95,485	Research payment	Cash or cash equivalent		PARTNER3 2015-08	2019
2019-12-23	Edwards Lifesciences Corporation	$4,976	Research payment	Cash or cash equivalent		Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study 2017-19	2019
2019-12-20	ABBVIE INC.	$4,222	Research payment	Cash or cash equivalent	Humira Biological, Immunology	P11-292	2019
2019-12-20	Edwards Lifesciences Corporation	$2,160	Research payment	Cash or cash equivalent		The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study 2016-05	2019
2019-12-19	AstraZeneca Pharmaceuticals LP	$5,000	Research payment	Cash or cash equivalent	IMFINZI Drug, Oncology	A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t	2019
2019-12-19	Sterilmed, Inc.	$1,178	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-12-19	Ipsen Innovation	$500	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluat	2019
2019-12-19	ARRAY BIOPHARMA INC	$400	Research payment	Cash or cash equivalent	Braftovi Drug, Melanoma	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-	2019
2019-12-18	Edwards Lifesciences Corporation	$29,978	Research payment	Cash or cash equivalent		CLASP IIF 2018-07	2019
2019-12-18	Edwards Lifesciences Corporation	$18,607	Research payment	Cash or cash equivalent		The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study 2016-05	2019
2019-12-18	Edwards Lifesciences Corporation	$14,984	Research payment	Cash or cash equivalent		CLASP IID 2018-07	2019
2019-12-18	Edwards Lifesciences Corporation	$1,828	Research payment	Cash or cash equivalent		Edwards PASCAL Transcatheter Valve Repair System in Tricuspid Regurgitation CLASP TR Early Feasibility Study	2019
2019-12-16	ImClone Systems, LLC	$26,304	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-12-13	Edwards Lifesciences Corporation	$41,814	Research payment	Cash or cash equivalent		Early-TAVR Trial 2016-07	2019
2019-12-13	Edwards Lifesciences Corporation	$25,025	Research payment	Cash or cash equivalent	EDWARDS INTUITY Elite valve system Device, Pericardial Heart Valves	TRANSFORM 2011-02	2019
2019-12-13	Medtronic Vascular, Inc.	$2,585	Research payment	Cash or cash equivalent		ECG Belt	2019
2019-12-13	Medical Device Business Services, Inc.	$500	Research payment	Cash or cash equivalent		Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma	2019
2019-12-13	Medical Device Business Services, Inc.	$500	Research payment	Cash or cash equivalent		Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma	2019
2019-12-12	BioMarin Pharmaceutical Inc.	$2,070	Research payment	Cash or cash equivalent	Palynziq Drug, PKU	An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day	2019
2019-12-12	Ipsen Innovation	$500	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluat	2019
2019-12-11	Edwards Lifesciences Corporation	$26,668	Research payment	Cash or cash equivalent		Trial 2017-18 ExCEED	2019
2019-12-11	Edwards Lifesciences Corporation	$500	Research payment	Cash or cash equivalent		Trial 2017-18 ExCEED	2019
2019-12-10	Edwards Lifesciences Corporation	$13,013	Research payment	Cash or cash equivalent		PARTNER3 2015-08	2019
2019-12-10	Edwards Lifesciences Corporation	$8,669	Research payment	Cash or cash equivalent		The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study 2016-05	2019
2019-12-10	Medtronic, Inc.	$1,676	Research payment	Cash or cash equivalent	Attain Device, Leads	PSR-CVG	2019
2019-12-10	Edwards Lifesciences Corporation	$720	Research payment	Cash or cash equivalent	Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves	Early-TAVR Trial 2016-07	2019
2019-12-09	Merck Sharp & Dohme LLC	$41	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$35	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$33	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$23	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$15	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$4	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-12-05	Regeneron Pharmaceuticals, Inc.	$2,000	Research payment	Cash or cash equivalent	LIBTAYO Biological, ONCOLOGY	A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CE	2019
2019-12-05	PFIZER INC.	$1,200	Research payment	Cash or cash equivalent		A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINEBASED IMMUN	2019
2019-12-05	Abbott Laboratories	$552	Research payment	Cash or cash equivalent	ABSORB Device, Vascular	A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects	2019
2019-12-04	Edwards Lifesciences Corporation	$12,037	Research payment	Cash or cash equivalent		CLASP II TR Pivotal, Study No. 2019-07	2019
2019-12-04	Edwards Lifesciences Corporation	$2,200	Research payment	Cash or cash equivalent		Early Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation TMVI System 2013-05C	2019
2019-12-04	Edwards Lifesciences Corporation	$1,459	Research payment	Cash or cash equivalent	Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves	Early-TAVR Trial 2016-07	2019
2019-12-04	Edwards Lifesciences Corporation	$385	Research payment	Cash or cash equivalent		Edwards Cardioband System ACTIVE Pivotal Clinical Trial 2017-05	2019
2019-12-04	Medtronic Vascular, Inc.	$250	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	CoreValve SURTAVI	2019
2019-12-04	Medtronic Vascular, Inc.	$250	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	CoreValve SURTAVI	2019
2019-12-03	Medtronic Vascular, Inc.	$250	Research payment	Cash or cash equivalent		CoreValve CAS	2019
2019-12-03	Medtronic Vascular, Inc.	$250	Research payment	Cash or cash equivalent		CoreValve CAS	2019
2019-12-02	Eli Lilly and Company	$2,000	Research payment	Cash or cash equivalent		A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED PHASE II STUDY OF ENZALUTAMIDE WITH OR WITHOUT THE PI3 KINASE-MTOR INHI	2019
2019-12-02	GENZYME CORPORATION	$333	Research payment	Cash or cash equivalent	POMPE - DISEASE Drug	Pompe LSD Data Registry	2019
2019-12-02	GENZYME CORPORATION	$333	Research payment	Cash or cash equivalent	GAUCHER-DISEASE Drug	Gaucher LSD Data Registry	2019
2019-12-02	GENZYME CORPORATION	$333	Research payment	Cash or cash equivalent	FABRY-DISEASE Drug	Fabry LSD Data Registry	2019
2019-12-02	Lilly USA, LLC	$100	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-11-27	Edwards Lifesciences Corporation	$16,362	Research payment	Cash or cash equivalent	Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves	SM3 Trial 2017-03	2019
2019-11-27	Edwards Lifesciences Corporation	$10,354	Research payment	Cash or cash equivalent		Partner3 2015-08	2019
2019-11-27	ABBVIE INC.	$500	Research payment	Cash or cash equivalent	Humira Biological, Immunology	P11-292	2019
2019-11-26	Edwards Lifesciences Corporation	$10,017	Research payment	Cash or cash equivalent		MiBAND 2017-10	2019
2019-11-26	BioMarin Pharmaceutical Inc.	$4,237	Research payment	Cash or cash equivalent		A Prospective Clinical Study of Phenylketonuria (PKU)	2019
2019-11-21	Insmed, Inc.	$2,250	Research payment	Cash or cash equivalent		Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolera	2019
2019-11-20	Edwards Lifesciences Corporation	$95,645	Research payment	Cash or cash equivalent		CLASP IID 2018-07	2019
2019-11-20	Edwards Lifesciences Corporation	$42,267	Research payment	Cash or cash equivalent		The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study 2016-05	2019
2019-11-20	GE HEALTHCARE	$8,000	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Device, MAGNETIC RESONANCE		2019
2019-11-20	Medical Device Business Services, Inc.	$450	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ORTHOVISC Device, Sports Early Intervention		2019
2019-11-19	Sterilmed, Inc.	$1,074	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-11-19	BioMarin Pharmaceutical Inc.	$598	Research payment	Cash or cash equivalent	Palynziq Drug, PKU	An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day	2019
2019-11-18	TESARO, Inc.	$34,568	Research payment	In-kind items and services	ZEJULA Drug, ONCOLOGY	A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER	2019
2019-11-18	ImClone Systems, LLC	$24,841	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-11-18	Janssen Research & Development, LLC	$1,000	Research payment	Cash or cash equivalent		A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo	2019
2019-11-18	GENZYME CORPORATION	$260	Research payment	Cash or cash equivalent	GAUCHER-DISEASE Drug	Gaucher LSD Data Registry	2019
2019-11-14	Abbott Laboratories	$1,500	Research payment	Cash or cash equivalent	HeartMate PHP Device, Cardiac Arrhythmias and Heart Failure	Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II)	2019
2019-11-14	ABBVIE INC.	$1,250	Research payment	Cash or cash equivalent	Rinvoq Biological, Immunology	M14-234	2019
2019-11-14	Abbott Laboratories	$250	Research payment	Cash or cash equivalent	HeartMate PHP Device, Cardiac Arrhythmias and Heart Failure	Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II)	2019
2019-11-13	Edwards Lifesciences Corporation	$12,037	Research payment	Cash or cash equivalent		Early Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation TMVI System 2013-05C	2019
2019-11-13	Medtronic Vascular, Inc.	$11,112	Research payment	Cash or cash equivalent	Evera Device, Implantable Cardioverter Defibrillators (ICDs)	Tachy Prediction Download	2019
2019-11-13	PFIZER INC.	$2,250	Research payment	Cash or cash equivalent	BAVENCIO Drug, ONCOLOGY	A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS	2019
2019-11-13	Allergan, Inc.	$750	Research payment	Cash or cash equivalent	LINZESS Drug, GASTROENTEROLOGY	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Lin	2019
2019-11-13	BioMarin Pharmaceutical Inc.	$500	Research payment	Cash or cash equivalent		Morquio A Registry Study (MARS)	2019
2019-11-12	Edwards Lifesciences Corporation	$16,060	Research payment	Cash or cash equivalent	EDWARDS INTUITY Elite valve system Device, Pericardial Heart Valves	TRANSFORM 2011-02	2019
2019-11-11	Abbott Laboratories	$1,000	Research payment	Cash or cash equivalent	Xience V coronary stent system Device, Vascular	DAPT study	2019
2019-11-11	Abbott Laboratories	$525	Research payment	Cash or cash equivalent	Mitra Clip system Device, Vascular	Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitr	2019
2019-11-08	Abbott Laboratories	$250	Research payment	Cash or cash equivalent	Optim ICD Device, Cardiac Arrhythmias and Heart Failure	Optim Lead Insulation Material (OPTIMUM) Registry	2019
2019-11-08	Allergan, Inc.	$250	Research payment	Cash or cash equivalent	LINZESS Drug, GASTROENTEROLOGY	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Lin	2019
2019-11-07	Edwards Lifesciences Corporation	$14,245	Research payment	Cash or cash equivalent	EDWARDS INTUITY Elite valve system Device, Pericardial Heart Valves	TRANSFORM 2011-02	2019
2019-11-06	Edwards Lifesciences Corporation	$96,195	Research payment	Cash or cash equivalent		CLASP IID 2018-07	2019
2019-11-06	Edwards Lifesciences Corporation	$58,025	Research payment	Cash or cash equivalent		The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study 2016-05	2019
2019-11-06	ABBVIE INC.	$1,250	Research payment	Cash or cash equivalent	Rinvoq Biological, Immunology	M14-533	2019
2019-11-05	Takeda Pharmaceuticals U.S.A., Inc.	$15,455	Research payment	Cash or cash equivalent	ENTYVIO Biological, Lower GI	Entyvio-Vedolizumab- Long Term Study	2019
2019-11-01	Edwards Lifesciences Corporation	$19,257	Research payment	Cash or cash equivalent		CLASP IID 2018-07	2019
2019-11-01	Medical Device Business Services, Inc.	$7,000	Research payment	Cash or cash equivalent		Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma	2019
2019-11-01	Medical Device Business Services, Inc.	$4,000	Research payment	Cash or cash equivalent		Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma	2019
2019-10-31	Edwards Lifesciences Corporation	$18,865	Research payment	Cash or cash equivalent	EDWARDS INTUITY Elite valve system Device, Pericardial Heart Valves	TRANSFORM 2011-02	2019
2019-10-31	Edwards Lifesciences Corporation	$2,310	Research payment	Cash or cash equivalent		Commence Pulmonary Study 2015-03	2019
2019-10-30	Edwards Lifesciences Corporation	$8,750	Research payment	Cash or cash equivalent		Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial 2018-02	2019
2019-10-30	Edwards Lifesciences Corporation	$885	Research payment	Cash or cash equivalent		Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial 2018-02	2019
2019-10-30	Medtronic Vascular, Inc.	$500	Research payment	Cash or cash equivalent		ECG Belt	2019
2019-10-30	Cardiovascular Systems Inc.	$326	Research payment	Cash or cash equivalent	Coronary Orbital Atherectomy System Device, Atherectomy Device	ECLIPSE	2019
2019-10-30	Edwards Lifesciences Corporation	$100	Research payment	Cash or cash equivalent		Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System Trial 2018-02	2019
2019-10-29	BioMarin Pharmaceutical Inc.	$2,070	Research payment	Cash or cash equivalent	Palynziq Drug, PKU	An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day	2019
2019-10-29	TESARO, Inc.	$1,250	Research payment	Cash or cash equivalent	ZEJULA Drug, ONCOLOGY	PHASE 12 CLINICAL STUDY OF NIRAPARIB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NE	2019
2019-10-28	Dynavax Technologies Corporation	$5,837	Research payment	Cash or cash equivalent	Intratumoral SD-101 Drug	A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R	2019
2019-10-24	Medtronic Vascular, Inc.	$4,780	Research payment	Cash or cash equivalent		Evolut R US IDE	2019
2019-10-24	Medtronic Vascular, Inc.	$4,780	Research payment	Cash or cash equivalent		Evolut R US IDE	2019
2019-10-23	Edwards Lifesciences Corporation	$19,144	Research payment	Cash or cash equivalent		CLASP IID 2018-07	2019
2019-10-23	Edwards Lifesciences Corporation	$10,731	Research payment	Cash or cash equivalent		Edwards PASCAL Transcatheter Valve Repair System in Tricuspid Regurgitation CLASP TR Early Feasibility Study	2019
2019-10-23	Edwards Lifesciences Corporation	$8,635	Research payment	Cash or cash equivalent		Early Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation TMVI System 2013-05C	2019
2019-10-23	Edwards Lifesciences Corporation	$7,331	Research payment	Cash or cash equivalent		Early Feasibility Study of the Edwards Tricuspid Transcatheter Repair System 2014-04	2019
2019-10-23	Sterilmed, Inc.	$1,277	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-10-23	Edwards Lifesciences Corporation	$1,050	Research payment	Cash or cash equivalent		Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study 2017-19	2019
2019-10-23	PORTOLA PHARMACEUTICALS, LLC	$550	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ANDEXXA Biological, HEMATOLOGY/NEUROLOGY		2019
2019-10-22	TESARO, Inc.	$17,284	Research payment	In-kind items and services	ZEJULA Drug, ONCOLOGY	A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER	2019
2019-10-22	ARRAY BIOPHARMA INC	$9,000	Research payment	Cash or cash equivalent	Braftovi Drug, Melanoma	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-	2019
2019-10-22	ARRAY BIOPHARMA INC	$2,000	Research payment	Cash or cash equivalent	Braftovi Drug, Melanoma	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-	2019
2019-10-22	ARRAY BIOPHARMA INC	$2,000	Research payment	Cash or cash equivalent	Braftovi Drug, Melanoma	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-	2019
2019-10-22	ARRAY BIOPHARMA INC	$1,000	Research payment	Cash or cash equivalent	Braftovi Drug, Melanoma	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-	2019
2019-10-22	ARRAY BIOPHARMA INC	$1,000	Research payment	Cash or cash equivalent	Braftovi Drug, Melanoma	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-	2019
2019-10-22	ARRAY BIOPHARMA INC	$750	Research payment	Cash or cash equivalent	Braftovi Drug, Melanoma	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-	2019
2019-10-21	SANOFI US SERVICES INC.	$14,761	Research payment	Cash or cash equivalent	SAR440340 Drug	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Saf	2019
2019-10-21	Abbott Laboratories	$10,880	Research payment	Cash or cash equivalent	Xience V coronary stent system Device, Vascular	DAPT study	2019
2019-10-21	Medtronic Vascular, Inc.	$4,171	Research payment	Cash or cash equivalent		CoreValve CAS	2019
2019-10-21	Medtronic Vascular, Inc.	$4,171	Research payment	Cash or cash equivalent		CoreValve CAS	2019
2019-10-18	ABBVIE INC.	$2,000	Research payment	Cash or cash equivalent	Humira Biological, Immunology	M11-290	2019
2019-10-18	ABBVIE INC.	$1,000	Research payment	Cash or cash equivalent	Humira Biological, Immunology	M11-290	2019
2019-10-18	ABBVIE INC.	$250	Research payment	Cash or cash equivalent	Humira Biological, Immunology	M11-290	2019
2019-10-17	BioMarin Pharmaceutical Inc.	$8,500	Research payment	Cash or cash equivalent		A Prospective Clinical Study of Phenylketonuria (PKU)	2019
2019-10-17	Astellas Pharma Global Development	$1,887	Research payment	Cash or cash equivalent	XTANDI Drug, ONCOLOGY	A RANDOMIZED STUDY OF ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE ENACT	2019
2019-10-17	Astellas Pharma Global Development	$1,000	Research payment	Cash or cash equivalent	XTANDI Drug, ONCOLOGY	A RANDOMIZED STUDY OF ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE ENACT	2019
2019-10-16	Edwards Lifesciences Corporation	$35,878	Research payment	Cash or cash equivalent		Early-TAVR Trial 2016-07	2019
2019-10-16	Edwards Lifesciences Corporation	$1,500	Research payment	Cash or cash equivalent		Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study 2017-19	2019
2019-10-16	Edwards Lifesciences Corporation	$1,080	Research payment	Cash or cash equivalent		Edwards PASCAL Transcatheter Valve Repair System in Tricuspid Regurgitation CLASP TR Early Feasibility Study	2019
2019-10-16	Edwards Lifesciences Corporation	$1,000	Research payment	Cash or cash equivalent		Early Feasibility Study of the Edwards Tricuspid Transcatheter Repair System 2014-04	2019
2019-10-16	Edwards Lifesciences Corporation	$1,000	Research payment	Cash or cash equivalent		Early Feasibility Study of the Edwards Tricuspid Transcatheter Repair System 2014-04	2019
2019-10-16	Edwards Lifesciences Corporation	$540	Research payment	Cash or cash equivalent		CLASP IID 2018-07	2019
2019-10-16	Abbott Laboratories	$250	Research payment	Cash or cash equivalent	Optim ICD Device, Cardiac Arrhythmias and Heart Failure	Optim Lead Insulation Material (OPTIMUM) Registry	2019
2019-10-15	Merck Sharp & Dohme LLC	$21,652	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligibl	2019
2019-10-15	SANOFI US SERVICES INC.	$14,761	Research payment	Cash or cash equivalent	SAR440340 Drug	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Saf	2019
2019-10-14	E.R. Squibb & Sons, L.L.C.	$12,000	Research payment	Cash or cash equivalent		A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Backgro	2019
2019-10-14	Medtronic Vascular, Inc.	$5,129	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	CoreValve SURTAVI	2019
2019-10-14	Medtronic Vascular, Inc.	$5,129	Research payment	Cash or cash equivalent	CoreValve Evolut Device, Transcatheter Valve Systems	CoreValve SURTAVI	2019
2019-10-14	Edwards Lifesciences Corporation	$1,500	Research payment	Cash or cash equivalent		Trial 2017-18 ExCEED	2019
2019-10-11	ImClone Systems, LLC	$24,564	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-10-11	Edwards Lifesciences Corporation	$4,515	Research payment	Cash or cash equivalent		Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study 2017-19	2019
2019-10-11	Edwards Lifesciences Corporation	$1,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves		2019
2019-10-10	SANOFI PASTEUR INC.	$74,405	Research payment	Cash or cash equivalent	YELLOW FEVER Drug	STA00011 Stamaril Yellow Fever	2019
2019-10-10	Merck Sharp & Dohme LLC	$21,652	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-10	ARRAY BIOPHARMA INC	$4,000	Research payment	Cash or cash equivalent	Braftovi Drug, Melanoma	A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-	2019
2019-10-10	ABBVIE INC.	$1,000	Research payment	Cash or cash equivalent	Rinvoq Biological, Immunology	M14-234	2019
2019-10-10	Abbott Laboratories	$500	Research payment	Cash or cash equivalent	Mitra Clip system Device, Vascular	ardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitra	2019
2019-10-09	Edwards Lifesciences Corporation	$62,214	Research payment	Cash or cash equivalent		The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study 2016-05	2019
2019-10-08	Merck Sharp & Dohme LLC	$141	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$132	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$108	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$70	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$65	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$62	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$62	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$62	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$47	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$47	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$41	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$30	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$27	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$23	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$22	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligibl	2019
2019-10-08	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$13	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$12	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$12	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$11	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$11	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$9	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$7	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$7	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$4	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019
2019-10-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers	2019

The latest 200 records of 688.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In New Jersey; placed by its state only.

Measure	State New Jersey
Population B01003	9,343,809
Population, 2020 census P1	9,288,994
Median age B01002	40.1
Under 18 B01001	21.8%
65 and over B01001	17.2%
Households B11001	3,507,701
Foreign born B05002	23.9%
Median household income B19013	$103,556
Median family income B19113	$127,025
Per capita income B19301	$54,253
Poverty rate B17001	9.7%
Unemployment rate B23025	6.3%
Civilian labor force B23025	5,003,179
Mean commute (minutes) B08013	30.5
Bachelor's degree or higher B15003	43.6%
Housing units B25001	3,791,354
Owner-occupied B25003	63.8%
Renters B25003	36.2%
Median home value B25077	$454,400
Median gross rent B25064	$1,720
White, not Hispanic B03002	50.9%
Black B03002	12.2%
Hispanic or Latino B03002	22.5%
Asian B03002	10.0%
American Indian and Alaska Native B03002	0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Jersey.